C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with ANCA-Associated Vasculitis

Jae-Seung Moon¹, Sung Soo Ahn², Yong-Beom Park²,³, Sang-Kyou Lee¹,⁴, and Sang-Won Lee²,³
¹Department of Biotechnology, Yonsei University College of Life Science and Biotechnology, Seoul; ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul; ³Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul; ⁴Good T Cells, Inc., Seoul, Korea.

Purpose: We investigated whether C-reactive protein (CRP) to serum albumin ratio (CAR) could be an independent predictor of all-cause mortality in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Materials and Methods: We retrospectively reviewed the medical records of 170 patients with AAV. We collected clinical and laboratory data. We also examined AAV-related and traditional risk factors of all-cause mortality. To assess the hazard ratios of variables, we performed univariable and multivariable Cox hazard model analyses.
Results: The mean age was 55.0 years and 53 patients (31.2%) were male among 170 patients with AAV (88 microscopic polyangiitis, 43 granulomatosis with polyangiitis, and 39 eosinophilic granulomatosis with polyangiitis). ANCA was detected in 129 patients (75.9%). The initial mean CRP and serum albumin were 41.1 (mg/L) and 3.6 (g/dL), and the mean CAR at diagnosis was 14.8. The most common risk factor of mortality was hypertension (42.4%), followed by chronic kidney disease ≥ stage 3 (25.9%). Fourteen patients (8.2%) died during the mean follow-up of 56.7 months. In both multivariable Cox hazard model analyses, CAR at diagnosis was identified as an independent predictor of all-cause of mortality comparable to diabetes mellitus (DM). Moreover, patients with CAR ≥ 10.35 and having DM exhibited a higher frequency of all-cause mortality than those without.
Conclusion: CAR at diagnosis can be an independent predictor of all-cause mortality, comparable to DM, the conventional risk factor of mortality.
Key Words: Antineutrophil cytoplasmic antibody, vasculitis, c-reactive protein, albumin, mortality

INTRODUCTION

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides encroaching small vessels, from capillaries to intraparenchymal arterioles and venules. AAV consists of three variants, such as microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA).¹² Because AAV may induce damage to major organs, AAV can occasionally be fatal: One year-cumulative patient survival rates were reported to range from 82% to 95% in Western countries³ and up to 79.1% in Japan.⁴ Meanwhile, it was recently reported that 10-year cumulative patient survival rate was 92.8% in Korean patients with AAV.⁵
So far, C-reactive protein (CRP)/serum albumin ratio (CAR) has been introduced as an independent predictor of all-cause mortality in cancers, inflammatory diseases and septic conditions. Since, AAV is also an inflammatory disease involving systemic major organs beyond vessels, one could reasonably speculate that CAR might be a predictor of all-cause mortality during follow-up. However, no study has sought to clarify the clinical significance of CAR in predicting all-cause mortality in AAV patients. Hence, in this study, we investigated whether CAR could be an independent predictor of all-cause mortality in 170 patients with AAV.

MATERIALS AND METHODS

Patients
We retrospectively reviewed the medical records of 170 patients with AAV based on the following inclusion criteria: 1) patients who were first classified as AAV from October 2000 to September 2017 at the Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital; 2) patients who fulfilled the American College of Rheumatology 1990 criteria for the classification of GPA and EGPA and then reclassified by the algorithm suggested by the European Medicines Agency in 2007, in which the authors added the modified contents of the Chapel Hill Consensus Conferences Nomenclature of Vasculitis proposed in 2012; 3) patients who had well-documented medical records with which to assess both clinical manifestations at diagnosis and death during follow-up and to calculate vasculitis activity score represented by Birmingham vasculitis activity score (BVAS) and prognostic factors identified by five factor score (FFS, 2009) at diagnosis; and 4) patients who had results on perinuclear (P)-ANCA and cytoplasmic (C)-ANCA or myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-ANCA levels at diagnosis. This study was approved by the Institutional Review Board of Severance Hospital (4-2017-0673) who waived the need for the patient written informed consent, as this was a retrospective study.

Clinical and laboratory data
We obtained age at diagnosis and gender as demographic data. We collected clinical and laboratory results at diagnosis as described in Table 1. Comorbidities belonging to BVAS or FFS (2009), such as diffuse alveolar haemorrhage and cardiovascular diseases, were excluded in risk factors. We also reviewed medications administered during follow-up. We defined the follow-up duration as the period from diagnosis to the last visit in surviving patients, while we defined it as the period from diagnosis to death in deceased patients. CAR was calculated as CRP (mg/L) divided by serum albumin (g/dL).

Statistical analyses
All statistical analyses were conducted using SPSS software.

| Table 1. Baseline Characteristics of Patients with AAV (n=170) |
|---------------------------------------------------------------|
| **Variables**       | **Values**               |
| At diagnosis        |                           |
| Demographic data   |                           |
| Age at diagnosis (yr) | 55.0±15.4               |
| Male gender         | 53 (31.2)                |
| AAV variants        |                           |
| MPA                 | 88 (51.8)                |
| GPA                 | 43 (25.3)                |
| EGPA                | 39 (22.9)                |
| ANCA positivity     | 129 (75.9)               |
| MPO-ANCA (or P-ANCA)| 105 (61.8)               |
| PR3-ANCA (or C-ANCA)| 28 (16.5)                |
| Both ANCA           | 8 (4.7)                  |
| ANCA negative       | 41 (24.1)                |
| Clinical manifestations |                         |
| General             | 75 (44.1)                |
| Cutaneous           | 40 (23.5)                |
| Mucous membranes/eyes | 12 (7.1)                 |
| Ear Nose Throat     | 64 (37.6)                |
| Pulmonary           | 92 (54.1)                |
| Cardiovascular      | 46 (27.1)                |
| Abdominal           | 10 (5.9)                 |
| Renal               | 99 (58.2)                |
| Nervous systems     | 54 (31.8)                |
| Activity and prognostic factor |             |
| BVAS                | 12.8±7.0                 |
| FFS (2009)          | 1.2±1.0                  |
| Laboratory results  |                           |
| White blood cell (/mm³) | 9992.8±4678.5          |
| Haemoglobin (g/dL)  | 11.5±2.3                 |
| Platelet×10⁹ (/mm³) | 324.5±139.0              |
| Blood urea nitrogen (mg/dL) | 25.1±23.2         |
| Creatinine (mg/dL)  | 1.8±2.0                  |
| Protein (g/dL)      | 6.7±0.9                  |
| Serum albumin (g/dL) | 3.6±0.8                 |
| Alkaline phosphatase (IU/L) | 88.6±84.3            |
| Aspartate aminotransferase (IU/L) | 24.0±24.4          |
| Alanine aminotransferase (IU/L) | 23.5±35.3          |
| Total bilirubin     | 0.7±1.4                  |
| Acute reactants     |                           |
| Erythrocyte sedimentation rate (mm/hr) | 59.0±37.3           |
| C-reactive protein (mg/L) | 41.1±55.4            |
| CAR                 | 14.8±22.5                |
| Comorbidities except items of BVAS or FFS(2009) at diagnosis* |            |
| Chronic kidney disease≥stage 3 | 44 (25.9)           |
| End stage renal disease | 28 (16.5)             |
| Diabetes mellitus   | 34 (20.0)                |
| Hypertension        | 72 (42.4)                |
| Viral hepatitis     | 6 (3.5)                  |
DISCUSSION

In this study, we investigated whether CAR at diagnosis could predict all-cause mortality during the follow-up of AAV. Also, we demonstrated that CAR at diagnosis is an independent predictor of all-cause mortality comparable to DM, the conventional risk factor of mortality. Also we provided an optimal cut-off of CAR at diagnosis to estimate the risk of all-cause mortality.

How CAR at diagnosis could be an independent predictor of all-cause death in AAV patients could be explained as follows: CRP is closely correlated with interleukin (IL)-6. Chronic inflammation enhances the production of IL-6, which, in turn, promotes the production of CRP in the liver, leading to an increase in CRP level in the peripheral circulation.13 Meanwhile, IL-6 down-regulates or inhibits the production of albumin in the liver, resulting in a decrease in serum albumin concentration.14 Accordingly, inflammatory burden can affect CAR via two different directions (increasing CRP and decreasing serum albumin), unlike CRP or serum albumin alone. Thus, CAR with two variables affected by inflammatory burden in AAV could be a more stable and reliable index to presuppose all-cause mortality, compared to CRP or serum albumin alone in AAV patients.

Here we provide two hypotheses regarding the connection between the inflammatory burdens at diagnosis and all-cause mortality in AAV patients. First, a large inflammatory burdens at diagnosis may provoke immunosuppressive drug-refractoriness or cause a situation where patients should take larger doses of immunosuppressive drugs or have a longer period to

### RESULTS

#### Baseline characteristics of 170 patients with AAV

The baseline characteristics are described in Table 1. The mean age was 55.0 years and 53 patients (31.2%) were male. The mean BVAS and FFS (2009) at diagnosis were 12.8 and 1.2, respectively. The initial mean CRP and serum albumin levels were 41.1 (mg/L) and 3.6 (g/dL), respectively, and the mean CAR at diagnosis was 14.8. Fourteen patients (8.2%) died during the mean follow-up of 56.7 months.

#### CAR at diagnosis and all-cause mortality during the follow-up

In univariable Cox hazard model analysis, CAR at diagnosis was significantly associated with all-cause mortality in AAV patients [HR 1.037, 95% confidence interval (CI) 1.015–1.060], along with age, BVAS, FFS (2009) ≥2, haemoglobin, blood urea nitrogen, alkaline phosphatase, total bilirubin, erythrocyte sedimentation rate, chronic kidney disease (CKD) ≥stage 3 and DM at diagnosis. However, medications showed no predictive value for mortality (Table 2).

Since BVAS and FFS (2009) share some items, we separately performed multivariable analysis with either BVAS or FFS (2009) ≥2, along with other variables with significance in univariable analysis. In multivariable Cox hazards model analysis with BVAS, CAR (HR 1.048) and DM (HR 6.313) were independent predictors of all-cause mortality in AAV patients (Table 2). Meanwhile, in multivariable Cox hazards model analysis with FFS (2009) ≥2, only CAR (HR 1.039) was an independent predictor of all-cause death in AAV patients (Table 2).

#### Optimal cut-off of CAR to predict all-cause mortality

Cumulative patient survival rates according to CAR ≥10.35 and the presence of DM are depicted in Fig. 1. In Kaplan-Meier survival analysis, patients with CAR ≥10.35 exhibited a higher frequency of all-cause mortality than those without (p<0.001). Also, patients with DM also exhibited lower cumulative patient survival rate that those without (p=0.012).

### Table 1. Baseline Characteristics of Patients with AAV (n=170) (Continued)

| Variables | Values |
|-----------|--------|
| During follow-up | |
| Follow-up duration (months) | 56.7±54.4 |
| Death | 14 (8.2) |
| Medications administered | |
| Glucocorticoid | 145 (85.8) |
| Cyclophosphamide | 71 (42.0) |
| Mycophenolate mofetil | 10 (5.9) |
| Azathioprine | 46 (27.2) |
| Tacrolimus | 10 (5.9) |
| Rituximab | 15 (8.9) |
| Methotrexate | 13 (7.7) |

AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatisis with polyangiitis; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculitis activity score; FFS, five factor score; CAR, C-reactive protein to serum albumin ratio.

Values are expressed as a mean±standard deviation or number (%).

*p* values less than 0.05 were considered statistically significant.
## Table 2. Univariable and Multivariable Cox Hazard Model Analyses of Variables for All-Cause Death in AAV Patients during the Follow-Up (n=170)

| Variables at diagnosis                                      | Univariable analysis | Multivariable analysis (including BVAS at diagnosis) | Multivariable analysis (including FFS (2009) at diagnosis) |
|------------------------------------------------------------|----------------------|------------------------------------------------------|----------------------------------------------------------|
|                                                           | HR                   | 95% CI                                | p value         | HR                   | 95% CI                                | p value         | HR                   | 95% CI                                | p value         |
| Demographic data at diagnosis                              |                      |                                      |                 |                      |                                      |                 |                      |                                      |                 |
| Age                                                        | 1.052                | 1.009–1.097                         | 0.017           | 1.045                | 0.986–1.109                        | 0.137           | 1.033                | 0.973–1.096                        | 0.285           |
| Male gender                                                | 1.265                | 0.409–3.914                         | 0.683           |                      |                                      |                 |                      |                                      |                 |
| ANCA positivity at diagnosis                               | 3.779                | 0.638–17.037                        | 0.084           |                      |                                      |                 |                      |                                      |                 |
| Activity and prognostic factor                             |                      |                                      |                 |                      |                                      |                 |                      |                                      |                 |
| BVAS                                                       | 1.092                | 1.014–1.177                         | 0.021           | 0.996                | 0.982–1.009                        | 0.025           | N/A                  | N/A                                 | N/A             |
| FFS (2009) ≥2                                              | 10.101               | 2.242–45.517                        | 0.003           | N/A                  | N/A                                 | N/A             | 6.175                | 0.632–60.319                        | 0.117           |
| Laboratory results at diagnosis                            |                      |                                      |                 |                      |                                      |                 |                      |                                      |                 |
| White blood cell                                           | 1.000                | 1.000–1.000                         | 0.743           |                      |                                      |                 |                      |                                      |                 |
| Haemoglobin                                                | 0.651                | 0.480–0.884                         | 0.006           | 0.763                | 0.477–1.219                        | 0.258           | 0.864                | 0.523–1.426                        | 0.566           |
| Platelet                                                   | 1.000                | 0.995–1.004                         | 0.944           |                      |                                      |                 |                      |                                      |                 |
| Blood urea nitrogen                                        | 1.014                | 1.002–1.026                         | 0.020           | 1.018                | 0.992–1.046                        | 0.176           | 1.012                | 0.989–1.036                        | 0.295           |
| Creatinine                                                 | 1.098                | 0.929–1.298                         | 0.274           |                      |                                      |                 |                      |                                      |                 |
| Protein*                                                   | 0.398                | 0.192–0.823                         | 0.013           | N/A                  | N/A                                 | N/A             | N/A                  | N/A                                 | N/A             |
| Serum albumin*                                             | 0.138                | 0.046–0.414                         | <0.001          | N/A                  | N/A                                 | N/A             | N/A                  | N/A                                 | N/A             |
| Alkaline phosphatase                                       | 1.004                | 1.001–1.007                         | 0.022           | 1.000                | 0.991–1.008                        | 0.950           | 1.001                | 0.994–1.008                        | 0.826           |
| Aspartate aminotransferase (IU/L)                          | 1.008                | 0.988–1.018                         | 0.124           |                      |                                      |                 |                      |                                      |                 |
| Alanine aminotransferase (IU/L)                            | 1.006                | 0.988–1.013                         | 0.168           |                      |                                      |                 |                      |                                      |                 |
| Total bilirubin                                            | 1.152                | 1.022–1.298                         | 0.021           | 1.135                | 0.787–1.639                        | 0.498           | 1.080                | 0.785–1.485                        | 0.638           |
| Acute phase reactants at diagnosis                         |                      |                                      |                 |                      |                                      |                 |                      |                                      |                 |
| Erythrocyte sedimentation rate (mm/hr)                     | 1.018                | 1.001–1.035                         | 0.032           | 1.004                | 0.976–1.033                        | 0.782           | 1.011                | 0.980–1.042                        | 0.499           |
| C-reactive protein (mg/L)*                                 | 1.014                | 1.004–1.023                         | 0.006           | N/A                  | N/A                                 | N/A             | N/A                  | N/A                                 | N/A             |
| CAR at diagnosis                                           | 1.037                | 1.015–1.060                         | 0.001           | 1.048                | 1.009–1.089                        | 0.016           | 1.039                | 1.003–1.077                        | 0.036           |
| Comorbidities except items of BVAS or FFS (2009) at diagnosis†|                      |                                      |                 |                      |                                      |                 |                      |                                      |                 |
| Chronic kidney disease ≥ stage 3                          | 3.883                | 1.253–12.031                        | 0.019           | 4.236                | 0.750–23.930                      | 0.102           | 3.419                | 0.570–20.517                      | 0.179           |
| End stage renal disease                                   | 1.140                | 0.346–3.757                         | 0.829           |                      |                                      |                 |                      |                                      |                 |
| Diabetes mellitus                                          | 3.939                | 1.239–12.526                        | 0.020           | 6.313                | 1.120–35.571                      | 0.037           | 4.024                | 0.817–19.813                      | 0.087           |
| Hypertension                                              | 2.834                | 0.866–9.386                         | 0.088           |                      |                                      |                 |                      |                                      |                 |
receive them. This situation may exacerbate the risk of infection and cancer development. Second, a large inflammatory burden may reflect ready-made organ-damage at diagnosis and, furthermore, may result in end stage damage to various major organs during follow-up, such as diffuse alveolar haemorrhage and end stage renal disease. This situation may aggravate the systemic complications of organ-damages by AAV, leading to an increase in all-cause mortality. In this study, the most common cause of death was serious infection in 12 patients [pneumonia (n=7), bacterial sepsis (n=3), influenza infection (n=1), and biliary infection (n=1)]. Two patients died of AAV-related complication [diffuse alveolar haemorrhage (n=1) and cardiac arrest due to cardiomyopathy (n=1)]. This result might support to our hypotheses.

Table 2. Univariable and Multivariable Cox Hazard Model Analyses of Variables for All-Cause Death in AAV Patients during the Follow-Up (n=170) (Continued)

| Variables at diagnosis | Univariable analysis (including BVAS at diagnosis) | Multivariable analysis (including FFS (2009) at diagnosis) |
|------------------------|---------------------------------------------------|----------------------------------------------------------|
|                         | HR 95% CI p value                                 | HR 95% CI p value                                         |
| Viral hepatitis         | 2.209 0.275–17.799 0.456                         |                                                          |
| Medications administered during follow-up | 0.865 0.191–3.927 0.851 |                                                          |
| Glucocorticoid          | 1.865 0.622–5.504 0.240                          |                                                          |
| Cyclophosphamide        | 1.871 0.404–8.664 0.423                          |                                                          |
| Mycophenolate mofetil   | 0.136 0.027–1.628 0.136                          |                                                          |
| Azathioprine            | 0.028 0.000–18.799 0.282                          |                                                          |
| Tacrolimus              | 0.023 0.000–10.735 0.210                          |                                                          |
| Rituximab               | 0.029 0.000–10.735 0.210                          |                                                          |

AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis activity score; FFS, five factor score; CAR, C-reactive protein to serum albumin ratio; HR, hazard ratio; CI, confidence interval.

*Protein, serum albumin and CRP were excluded in multivariable Cox hazard model analyses, because they are variables related to the equation for CAR.

†Interstitial lung disease, diffuse alveolar haemorrhage, ischaemic heart diseases-related diseases, and cerebrovascular accident-related diseases were excluded as comorbidities.

Fig. 1. A predictor of all cause-mortality in ANCA-associated vasculitis patients. Patients with CAR ≥10.35 and having DM exhibited a higher frequency of all-cause mortality than those without in Kaplan-Meier survival analysis. ANCA, antineutrophil cytoplasmic antibody; CAR, C-reactive protein to serum albumin ratio; DM, diabetes mellitus.
cause mortality.15 Meanwhile, age, male gender, DM, and hypertension are also considered as traditional risk factors of all-cause mortality in the general population.15 Recently, in Korean patients with AAV, it was reported that FFS (2009) at diagnosis ≥2 was associated with mortality.5 Accordingly, we included initial BVAS and FFS (2009) at diagnosis ≥2 in multivariable Cox hazard model analysis along with both AAV-related and traditional risk factors of all-cause mortality. In univariable analysis, almost all the risk factors exhibited predictive potential for mortality, similar to a previous study.14 However, in both multivariable Cox hazards model analyses with either initial BVAS or FFS (2009) at diagnosis ≥2, only CAR at diagnosis and DM were identified as an independent predictor of all-cause mortality. Unlike the previous study investigating whether the initial clinical features and medications administered could predict all-cause mortality,5 this study evaluated the clinical implications of CAR among clinical and laboratory variables, and so there might be a subtle difference in the results between the two studies.

Although no predictive value for all-cause mortality was witnessed in ANCA positivity (p=0.084) or hypertension (p=0.088) in the univariable Cox hazards model analysis in this study, ANCA positivity is one of AAV-related risk factors for serious outcomes,16 and furthermore, hypertension is a well-known conventional risk factor for mortality in the general population.17 Thus, to minimise the effect of two confounding factors, we included ANCA positivity and hypertension in the univariable Cox hazard model analysis. Regardless of ANCA positivity and hypertension, only CAR exhibited statistical significance among variables when applying either BVAS at diagnosis or FFS (2009) at diagnosis ≥2 in the model (HR 1.050, p=0.025, and HR 1.042, p=0.039) (Supplementary Table 1, only online).

Our study has an advantage in that we first proved the clinical significance of CAR at diagnosis in predicting all-cause of mortality and furthermore, provided an optimal cut-off of CAR at diagnosis to estimate the risk of all-cause mortality. However, this study also has several limitations. First, as this study was designed as a retrospective study, we could not strictly control for confounding factors, including undocumented histories of medications, nutritional status related the level of serum albumin, and comorbidities. Second, as this study was conducted in a single centre, the number of deceased patients was too small to perform sub-group analysis based on the causes of mortality. Third, we could not use the cut-off of CAR in the multivariable Cox hazard model analysis to presuppose all-cause mortality due to the small statistical power. This study may be a pilot study to first investigate the clinical implication of CAR in AAV patients. We believe that future prospective and multi-centric studies will validate the clinical implications of our results, and they will provide a clear optimal cut-off of CAR to predict all-cause mortality in AAV patients for use in real clinical settings. In conclusion, CAR at diagnosis can be an independent predictor of all-cause mortality, comparable to DM, the conventional risk factor of mortality.

ACKNOWLEDGEMENTS

This work was also supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2017R1A2A1A17069807); Global Research Laboratory (GRL) Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2016K1A1A2912755).

ORCID

Sang-Kyou Lee https://orcid.org/0000-0002-3272-9264
Sang-Won Lee https://orcid.org/0000-0002-8038-3341

REFERENCES

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
2. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
3. Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis 2017;76:1566-74.
4. Yamagata K, Usui J, Saito C, Yamaguchi N, Hirayama K, Mase K, et al. ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes. Clin Exp Nephrol 2012;16:580-8.
5. Mun CH, Yoo J, Jung SM, Song JJ, Park YB, Lee SW. The initial predictors of death in 153 patients with ANCA-associated vasculitis in a single Korean centre. Clin Exp Rheumatol 2018;36 Suppl 111:65-72.
6. Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T, et al. Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep 2015;5:10481.
7. Qin G, Tu J, Liu L, Luo L, Wu J, Tao L, et al. Serum albumin and C-reactive protein/albumin ratio are useful biomarkers of Crohni’s disease activity. Med Sci Monit 2016;22:4393-400.
8. Kim MH, Ahn JY, Song JE, Choi H, Ann HW, Kim JK, et al. The C-reactive protein/albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. PLoS One 2015;10:e0132109.
9. Mukhtyar C, Lee B, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
10. Guillemin L, Pagnoux C, Seror R, Mahr A, Mouton L, Le Toumelin P; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011;90:19-27.
11. Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology; biology and genetics. Nat Rev Rheumatol 2011;7:282-9.
12. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shinya M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012;122:143-59.
13. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6:638-47.
14. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.
15. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591-608.
16. Durel CA, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken) 2016;68:374-87.